相关实验视频

Updated: May 12, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

通过多omics分析确定了乳头甲状腺癌的新治疗点和机制

Jianxiong Xu¹, Chen Gao²

¹Department of Radiation Oncology, The First Hospital of Putian City, Putian, Fujian, China.

Discover oncology

|May 8, 2025

概括

研究人员确定LY75和S100A12是乳头甲状腺癌 (PTC) 的潜在新治疗点. 多omics分析探索了它们在PTC发展中的作用,为治疗提供了新的途径.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
蛋白质组学是指蛋白质组学.

背景情况:

乳头甲状腺癌 (PTC) 治疗面临挑战,需要发现新的治疗点.
目前用于PTC的治疗策略需要通过创新的方法来增强.

研究的目的:

通过使用多omics方法来确定 papillary thyroid carcinoma (PTC) 的新型治疗点.
调查已识别的目标在PTC发病过程中的潜在机械作用.

主要方法:

蛋白质门德尔随机化 (MR) 分析整合了全基因组关联研究 (GWAS) 和蛋白质定量特征位置 (pQTL) 数据.
分析使用了deCODE和英国生物库蛋白质项目 (UKB-PP) 的蛋白质组数据,以及芬兰联盟的PTC GWAS数据.
使用eQTL验证,生物信息学差异分析和调解分析来识别和验证治疗点及其机制.

主要成果:

两种潜在的治疗点,LY75和S100A12,被确定与乳头甲状腺癌 (PTC) 有显著关联.
调解分析提供了对LY75和S100A12可能影响PTC病变的潜在机制途径的见解.

结论:

多omics分析成功地确定了 papillary 甲状腺癌的新型潜在治疗点.
该研究阐明了确定目标的潜在潜在机制,为PTC的未来治疗开发铺平了道路.

关键词:

生物信息学分析分析这就是Cis-pQTL.在EQTL中,EQTL是最重要的.调解调解是一种调解.门德尔的随机化乳头甲状腺癌是一种乳头甲状腺癌.

更多相关视频

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Canonical Wnt Signaling Pathway

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...